What was the conclusion of the meta-analysis of prospective randomized controlled trials comparing intracoronary versus intravenous abciximab in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention?
The meta-analysis of prospective randomized controlled trials comparing intracoronary versus intravenous abciximab in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention concluded that there was no significant difference in the clinical outcomes between the two groups. Additionally, researchers found that there was no difference in the incidence of major bleeding or thrombocytopenia between the intracoronary and intravenous abciximab groups.